IMIDs present highly significant therapeutic challenges as they remain incurable, patients often present with comorbidities, and both the primary disease and its comorbid conditions can have a significant negative impact on quality of life [ 1 ].
← all excerpts
Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE Study.
1
—
—